Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Intellia Thera CS (NQ: NTLA )

53.40 -0.01 (-0.02%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 27, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,556,409
Open 53.88
Bid (Size) 52.00 (1)
Ask (Size) 54.80 (10)
Prev. Close 53.41
Today's Range 51.07 - 54.55
52wk Range 37.08 - 202.73
Shares Outstanding 74,672,427
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Intellia's Gene-Editing Candidate Shows Durability In ATTR Amyloidosis
 
Via Benzinga
BMO Initiates Coverage On This Gene Editing Spearhead
 
Via Benzinga

Performance

YTD
-55.00%
-55.00%
1 Month
+15.73%
+15.73%
3 Month
-26.93%
-26.93%
6 Month
-55.40%
-55.40%
1 Year
-59.98%
-59.98%

More News

Read More
Analyst Ratings for Intellia Therapeutics
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 16, 2022
Via Benzinga
Analyst Ratings for Intellia Therapeutics
Via Benzinga
4 Analysts Have This to Say About Intellia Therapeutics
Via Benzinga
10 Biggest Price Target Changes For Monday
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Via Benzinga
Earnings Preview For Intellia Therapeutics
Via Benzinga
How To Attend Intellia Therapeutics Q1 2022 Earnings Conference Call
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022
Via Benzinga
Good Entry Point for Biotech Stocks
Via Talk Markets
FDA Recommends At Least 15 years Of Follow-Up For Genome Editing Product Trials
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Here's How Much $100 Invested In Intellia Therapeutics 5 Years Ago Would Be Worth Today
Via Benzinga
Intellia's CRISPR-Engineered Cell Therapy Receives FDA Orphan Drug Tag For Bone Marrow Cancer
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2022
Via Benzinga
63 Biggest Movers From Yesterday
Via Benzinga
44 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
80 Biggest Movers From Yesterday
Via Benzinga
Analyst Ratings For Intellia Therapeutics
Via Benzinga
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
Via Benzinga
Intellia Shares Updated Data On Gene Editing Durability In Rare Disease
Via Benzinga
Intellia Therapeutics Crashes As Patent Decision Clouds CRISPR Gene-Editing Test
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.